As regulatory and ethical pressures continue to limit animal testing, the need for predictive, human-relevant toxicological methods has never been greater, particularly for endpoints such as repeated dose toxicity.

View this on-demand webinar that explores a promising alternative to in vivo testing using an integrated intestine–liver–kidney microphysiological system (MPS). This session discusses a study evaluating a model compound in a three-organ circuit designed to simulate ADME and toxicokinetics in vitro.

The platform enables communication between organs through a simulated blood flow system with semipermeable membranes, generating kinetic, metabolism, and toxicity data that demonstrate consistency with in vivo reports.

Key Topics:

• The need for new toxicological methods, particularly for repeated dose toxicity
• Design and use of a simulated blood flow system to connect multiple organ compartments
• Determining fluid volumes and tissue mass to support multiple timepoint sampling
• Application of MPS platforms as new approach methodologies to enhance NGRA

Speakers: 

James McKim, PhD, DABT, GM-Executive Director, In Vitro Assay Services at LifeNet Health LifeSciences

Dr. McKim earned his doctorate in Biochemical and Molecular Toxicology and has spent his career focused on alternative methods for accessing the safety of drugs and chemicals. He has been a diplomat of the American Board of Toxicology for nearly 30 years. He was the founder of CeeTox a biotech focused on in vitro screening methods and IONTOX where he developed the MPS platform being discussed today. He has multiple patents focused on New Approach Methodologies (NAMS) and several manuscripts and book chapters. He is currently the GM and Executive Director of the Assay Services group for LifeNet Health LifeSciences. 

Kaushal Joshi, PhD, DABT, Principal Scientist at the Research Institute for Fragrance Materials (RIFM)

Kaushal Joshi, PhD, DABT, holds a master’s degree in pharmacology and a PhD in toxicology from St. John’s University in New York. He joined the Research Institute for Fragrance Materials (RIFM) in 2016 as a Postdoctoral Scientist, beginning a career focused on advancing fragrance safety science. Over the years, Dr. Joshi has developed broad expertise across multiple areas of toxicology, including genotoxicity, computational toxicology, repeated-dose toxicity, and reproductive toxicity, supporting a wide range of research initiatives that strengthen fragrance ingredient safety assessments. Today, he serves as a Principal Scientist at RIFM, contributing to both risk assessment and research programs, with a particular emphasis on the development and application of reliable non-animal approaches for fragrance safety evaluation—an area in which RIFM continues to lead innovation. Dr. Joshi became a Board-Certified Toxicologist in 2023, underscoring his commitment to scientific rigor, professional excellence, and leadership in the field of toxicology.

View On-Demand Webinar: Harnessing A Three-Organ MPS Model to Assess Drug and Chemical Safety